Academia Sinica

Kun-Hsien Lin

Chi-Huey Wong

Alice L Yu

Tai-Na Wu

Jia-Tsrong Jan

Yi-Ling Lin

Ya-Jen Chang

Jung-Tung Hung

Alice Yu

Edmond YS Cheng

Glycosphingolipids (GSLs) bearing &#x3b1;-glucose (&#x3b1;-Glc) that preferentially stimulate human invariant NKT (iNKT) cells are provided. GSLs with &#x3b1;-glucose (&#x3b1;-Glc) that exhibit stronger induction in humans (but weaker in mice) of cytokines and chemokines and expansion and/or activation of immune cells than those with &#x3b1;-galactose (&#x3b1;-Gal) are disclosed. GSLs bearing &#x3b1;-glucose (&#x3b1;-Glc) and derivatives of &#x3b1;-Glc with F at the 4 and/or 6 positions are provided. Methods for iNKT-independent induction of chemokines by the GSL with &#x3b1;-Glc and derivatives thereof are disclosed. Methods for immune stimulation in humans using GSLs with &#x3b1;-Glc and derivatives thereof are provided.

Human iNKT cell activation using glycolipids with altered glycosyl groups

Glycosphingolipids (GSLs) compositions and methods for iNKT-independent induction of chemokines are disclosed.

Human iNKT cell activation using glycolipids

The present disclosure relates to synthetic alpha-galactosyl ceramide (&#x3b1;-GalCer) analogs, and their use as immunotherapies. In one aspect. a method of activating a cytokine response in a subject includes administering an effective amount of a compound to a subject, wherein the subject has an adaptive immune system that includes a population of cells, the population including at least one lymphocyte and at least one antigen-presenting cell, and wherein the compound is represented by the structure of formula 1: 

Alpha-galactosyl ceramide analogs and their use as immunotherapies

Growing community of inventors

Taipei, Taiwan

Kun-Hsien Lin